Deaconess is administering monoclonal antibody medications with emergency use authorization to help prevent hospitalization for COVID-19.
Currently, we are administering the Regeneron product Casirivimab/Imdevimab.
These medications are given as an infusion treatment of mild-to-moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization.
Adults who are at high risk are defined as being having at least ONE of the following criteria:
- BMI ≥ 25
- Chronic Kidney Disease
- Immunosuppressive disease
- Currently receiving immunosuppressive treatment
- Age ≥ 65
- Age ≥ 55 AND have at least one of the following
- Cardiovascular disease
- COPD/chronic respiratory disease
Adult patients who are vaccinated, have at least one of the risk factors above, and/or are experiencing severe "breakthrough" symptoms, may also be eligible for this treatment.
Adolescents who are at high risk are defined as having at least ONE of the following criteria:
- BMI ≥ 85th percentile
- Sickle cell disease
- Congenital or acquired heart disease
- Neurodevelopmental disorders, such as Cerebral palsy
- Medical related technological dependence (ie tracheostomy, gastrostomy)
- Asthma or other chronic respiratory disease requiring daily maintenance medications
Adolescent patients who are vaccinated, have at least one of the risk factors above, and/or are experiencing severe "breakthrough" symptoms, may also be eligible for this treatment.
Monoclonal antibody infusion is NOT authorized for:
- Hospitalized patients due to COVID-19
- Patients on oxygen due to COVID-19 OR patients with SpO2 ≤ 93%
- Patients on chronic oxygen therapy that are requiring increased levels of oxygen due to COVID-19
- Patients with COVID-19 symptom onset ≥ 10 days
- Clinical trial data shows most benefit in patients with symptoms of 7 days or less
- Treatment should be started as early as possible
If you believe you are a candidate for monoclonal antibody treatment, schedule an appointment now with a Deaconess Clinic LIVE
provider. They will assess your symptoms and/or risks, and will schedule any needed appointments for treatment.
*Maryland Department of Health. What are Monoclonal Antibodies Infographic, Retrieved 2021, Aug 20, from https://health.maryland.gov/preparedness/Pages/Monoclonal-Antibodies-Treatment-for-COVID-19.aspx